A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects

NCT04839926 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: 0.5mg CY150112
DRUG: 1.5mg CY150112
DRUG: 4.5mg CY150112
DRUG: 10mg CY150112
DRUG: 18mg CY150112
DRUG: 24mg CY150112

Sponsor

Jiangsu Nhwa Pharmaceutical Co., Ltd.